Koji Hasegawa

The Role of VEGF-C and VEGF-D in Coronary Artery Disease: From Molecular Pathophysiology to Therapeutic Lymphangiogenesis.

Journal: Journal of atherosclerosis and thrombosis

Published: August 19, 2026

Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM.

Journal: European cardiology

Published: March 25, 2026

Lipid-lowering therapy: Evidence and future perspective.

Journal: JRSM cardiovascular disease

Published: March 05, 2026

Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: November 21, 2025

Immunoglobulin free light chain-κ in association with NT-proBNP levels after smoking cessation.

Journal: Future science OA

Published: September 07, 2025

Correction: Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure.

Journal: Journal of biomedical science

Published: August 27, 2025

Association Between Cardio-Ankle Vascular Index and Heart Failure Outcomes: Insights From a Prospective Multicenter Cohort.

Journal: JACC. Advances

Published: July 24, 2025

Identification of a universal three-body s-wave resonance in 10He.

Journal: Nature communications

Published: July 08, 2025

MicroRNA-33 inhibition ameliorates muscular dystrophy by enhancing skeletal muscle regeneration.

Journal: EMBO molecular medicine

Published: February 27, 2025

Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure.

Journal: Journal of biomedical science

Published: February 21, 2025

Reduction of hypokalaemia with finerenone: a drug or class-specific effect?

Journal: European heart journal. Cardiovascular pharmacotherapy

Published: November 10, 2024

10-Year Trends of Antithrombotic Therapy Status and Clinical Outcomes in Patients With Atrial Fibrillation and Renal Dysfunction　- The Fushimi AF Registry.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: October 30, 2024

The Role of VEGF-C and VEGF-D in Coronary Artery Disease: From Molecular Pathophysiology to Therapeutic Lymphangiogenesis.

The Role of VEGF-C and VEGF-D in Coronary Artery Disease: From Molecular Pathophysiology to Therapeutic Lymphangiogenesis.

Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM.

Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM.

Lipid-lowering therapy: Evidence and future perspective.

Lipid-lowering therapy: Evidence and future perspective.

Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300.

Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300.

Immunoglobulin free light chain-κ in association with NT-proBNP levels after smoking cessation.

Immunoglobulin free light chain-κ in association with NT-proBNP levels after smoking cessation.

Correction: Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure.

Correction: Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure.

Association Between Cardio-Ankle Vascular Index and Heart Failure Outcomes: Insights From a Prospective Multicenter Cohort.

Association Between Cardio-Ankle Vascular Index and Heart Failure Outcomes: Insights From a Prospective Multicenter Cohort.

Identification of a universal three-body s-wave resonance in 10He.

Identification of a universal three-body s-wave resonance in 10He.

MicroRNA-33 inhibition ameliorates muscular dystrophy by enhancing skeletal muscle regeneration.

MicroRNA-33 inhibition ameliorates muscular dystrophy by enhancing skeletal muscle regeneration.

Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure.

Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure.

Reduction of hypokalaemia with finerenone: a drug or class-specific effect?

Reduction of hypokalaemia with finerenone: a drug or class-specific effect?

10-Year Trends of Antithrombotic Therapy Status and Clinical Outcomes in Patients With Atrial Fibrillation and Renal Dysfunction - The Fushimi AF Registry.

10-Year Trends of Antithrombotic Therapy Status and Clinical Outcomes in Patients With Atrial Fibrillation and Renal Dysfunction - The Fushimi AF Registry.

10-Year Trends of Antithrombotic Therapy Status and Clinical Outcomes in Patients With Atrial Fibrillation and Renal Dysfunction　- The Fushimi AF Registry.

10-Year Trends of Antithrombotic Therapy Status and Clinical Outcomes in Patients With Atrial Fibrillation and Renal Dysfunction　- The Fushimi AF Registry.